Toward a rational, value-based drug benefit for Medicare

Area of Science:

• Health Policy
• Pharmaceutical Economics
• Government Healthcare Programs

Background:

• Medicare Part D faces significant challenges regarding drug pricing and benefit sustainability.
• Previous legislative attempts to allow government negotiation of drug prices have faced obstacles.
• The current structure of Medicare Part D necessitates exploring alternative reform strategies.

Purpose of the Study:

• To explore potential reforms for Medicare Part D, focusing on drug price negotiation and benefit structure.
• To analyze a proposed model where the Centers for Medicare and Medicaid Services (CMS) administers a public plan to compete with private Medicare Part D plans.
• To examine the design considerations for a CMS-administered plan and its potential to foster a more rational and sustainable drug benefit.

Main Methods:

• Policy analysis of Medicare Part D.
• Discussion of potential design elements for a CMS-administered competing plan.
• Examination of transition mechanisms toward a sustainable drug benefit structure.

Main Results:

• The failure of direct government negotiation highlights the need for alternative Medicare Part D reform approaches.
• A CMS-administered competing plan is presented as a viable option to introduce competition and market discipline.
• Key design issues for such a plan are identified, including its role in facilitating long-term sustainability.

Conclusions:

• A CMS-administered plan offers a potential pathway to address Medicare Part D's challenges.
• This model could facilitate a transition to a more rational and sustainable prescription drug benefit.
• Further examination of the design and implementation of such a competing plan is warranted.